IL-23 promotes tumour incidence and growth
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Chronic inflammation has long been associated with increased incidence of malignancy and similarities in the regulatory mechanisms have been suggested for more than a century. Infiltration of innate immune cells, elevated activities of matrix metalloproteases and increased angiogenesis and vasculature density are a few examples of the similarities between chronic and tumour-associated inflammation. Conversely, the elimination of early malignant lesions by immune surveillance, which relies on the cytotoxic activity of tumour-infiltrating T cells or intra-epithelial lymphocytes, is thought to be rate-limiting for the risk to develop cancer. Here we show a molecular connection between the rise in tumour-associated inflammation and a lack of tumour immune surveillance. Expression of the heterodimeric cytokine interleukin (IL)-23, but not of its close relative IL-12, is increased in human tumours. Expression of these cytokines antagonistically regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis. Finally, transplanted tumours are growth-restricted in hosts depleted for IL-23 or in IL-23-receptor-deficient mice. Although many strategies for immune therapy of cancer attempt to stimulate an immune response against solid tumours, infiltration of effector cells into the tumour tissue often appears to be a critical hurdle. We show that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17 also induces proliferative signaling in keratinocytes through Act1, a major facet of its impact in psoriasis and perhaps also explaining its involvement in skin tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“this pro-proliferative role likely contributes to the pathogenic effects of IL-17 in psoriasis, as well as potentially in skin cancer”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“In addition, as discussed above, IL-17 promotes proliferation of skin epithelial cells to promote tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Self-citationInterleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Self-citationOppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Self-citationMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Cited by
Items 301–400 of 1,000
EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion
Ziegler, A. I., Heidenreich, R., Braumüller, H., Wolburg, H., Weidemann, S., Mocikat, R., & Röcken, M. (2009) · Blood · doi:10.1182/blood-2008-08-175109 · Cited by 76
Immunoregulatory role of B7-H1 in chronicity of inflammatory responses.
Dong, H., & Chen, X. (2006) · PubMed · Cited by 85
Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses
de Souza, A. P. D., & Bonorino, C. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.88 · Cited by 85
Implications of anti-cytokine therapy in colorectal cancer and autoimmune diseases
Wang, K., Grivennikov, S. I., & Karin, M. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202201 · Cited by 80
“While the mechanism by which IL-17 promotes tumorigenesis remains elusive, raised levels of IL-23 and Th-17 cytokines were found in multiple types of human cancers including CRC.(46) 51 52 Importantly, the presence of a ‘Th17 signature’ in stage I and stage II human CRC signals poor prognosis and reduced disease-free…”
BackgroundInfluentialBatf-dependent Th17 cells critically regulate IL-23 driven colitis-associated colon cancer
Punkenburg, E., Vogler, T., Büttner, M., Amann, K., Waldner, M., Atreya, R., Abendroth, B., Mudter, J., Merkel, S., Gallmeier, E., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308227 · Cited by 73
Differentiation and function of pro-inflammatory Th17 cells
Dong, C. (2009) · Microbes and Infection · doi:10.1016/j.micinf.2009.04.001 · Cited by 81
“[41] J.”
High expression of indoleamine 2,3-dioxygenase gene in prostate cancer
Feder‐Mengus, C., Wyler, S. F., Hudolin, T., Ruszat, R., Bubendorf, L., Chiarugi, A., Pittelli, M. G., Weber, W. P., Bachmann, A., Gasser, T. C., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.023 · Cited by 72
“Conflicting data have ben reported regarding the capacity of IL-23 and IL-17 to favour or inhibit cancer growth (Benchetrit et al, 2002; Langowski et al, 2006; Numasaki et al, 2003).”
BackgroundPositive and negative influences of regulatory T cells on tumour immunity
Gallimore, A., & Simon, A. K. (2008) · Oncogene · doi:10.1038/onc.2008.269 · Cited by 85
“Though its impact on Treg activity is undefined, there is clearly a lower incidence of carcinogen-induced tumours in mice genetically deficient in IL-23 or treated with blocking antibodies (Langowski et al., 2006).”
InfluentialMechanisms of Local Immunoresistance in Glioma
Albesiano, E., Han, J. E., & Lim, M. K. (2009) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2009.08.008 · Cited by 75
Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo
Bosisio, D., Vulcano, M., Prete, A. D., Sironi, M., Salvi, V., Salogni, L., Riboldi, E., Leoni, F., Dinarello, C. A., Girolomoni, G., et al. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0708401 · Cited by 74
DeVoti, J. A., Rosenthal, D. W., Wu, R., Abramson, A. L., Steinberg, B. M., & Bonagura, V. R. (2008) · Molecular Medicine · doi:10.2119/2008-00060.devoti · Cited by 75
“The immune system also plays a complex role in regulating the growth and metastasis of malignancies (13,14); however, its role in the development of benign lesions is less well understood.”
BackgroundNie, W., Yu, T., Sang, Y., & Gao, X. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.048 · Cited by 81
Yusuf, N., Nasti, T. H., Long, J., Naseemuddin, M., Lucas, A. P., Xu, H., & Elmets, C. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5219 · Cited by 72
“On the other hand, IL-23 is required for IL-17–producing T cells (24, 25 ).”
BackgroundOft, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101325 · Cited by 77
“IL-23 deficiency also severely restricts the development of experimentally induced tumors accompanied by a deficiency of inflammatory mediators such as IL-17, tumor-promoting inflammatory metalloproteases and inflammation driven angiogenesis [40,41].”
BackgroundSelf-citationStructural basis of IL-23 antagonism by an Alphabody protein scaffold
Desmet, J., Verstraete, K., Bloch, Y., Lorent, E., Wen, Y., Devreese, B. V., Vandenbroucke, K., Loverix, S., Hettmann, T., Deroo, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms6237 · Cited by 73
Microbes and Inflammation in Colorectal Cancer
Kostic, A. D., Chun, E., Meyerson, M., & Garrett, W. S. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0101 · Cited by 69
“expression is upregulated inmany cancers including colorectal cancer (46, 47), and IL-23 receptor (IL-23R) blockade reduces intestinal inflammation and tumor growth in ApcMin/þ mice colonized with enterotoxigenic Bacteroides fragilis (48), Bacteria”
Advanced Colorectal Cancer Is Associated With Enhanced IL-23 and IL-10 Serum Levels
Stanilov, N., Miteva, L. D., Deliysky, T. S., Jovchev, J. P., & Stanilova, S. A. (2010) · Laboratory Medicine · doi:10.1309/lm7t43aqziupiowz · Cited by 71
Targeting tumor-associated acidity in cancer immunotherapy
Lacroix, R., Rozeman, E. A., Kreutz, M. P., Renner, K., & Blank, C. U. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2195-z · Cited by 77
IL-23 stabilizes an effector Treg cell program in the tumor microenvironment
Wertheimer, T., Zwicky, P., Rindlisbacher, L., Sparano, C., Vermeer, M., de Melo, B. M. S., Haftmann, C., Rückert, T., Sethi, A., Schärli, S., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01755-7 · Cited by 73
Th17 Differentiation and Their Pro-inflammation Function
Song, X., Gao, H., & Qian, Y. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-9487-9_5 · Cited by 74
“Both IL-17A and IL-23 were also found to promote other cancers such as cutaneous chemical carcinogenesis, as Il17a-, Il17ra-, or Il23p19deficient mice developed remarkably decreased skin tumors [91, 141, 288].”
BackgroundReich, K., Papp, K. A., Armstrong, A. W., Wasfi, Y. S., Li, S., Shen, Y., Randazzo, B. P., Song, M., & Kimball, A. B. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17454 · Cited by 73
Association of plasma endotoxin, inflammatory cytokines and risk of colorectal adenomas
Kang, M. S., Edmundson, P., Araújo-Pérez, F., McCoy, A. N., Galanko, J. A., & Keku, T. O. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-91 · Cited by 76
“Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M: IL-23 promotes tumour incidence and growth.”
Backgroundder Most, R. G. V., Currie, A. J., Robinson, B. W. S., & Lake, R. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402255 · Cited by 80
“Importantly, mice deficient for the Th17 growth factor IL-23 are resistant to tumor growth.(72) Thus, it is possible that tumor cells have been selected to survive under inflammatory conditions, as long as specific cytotoxic T cell responses are kept under control.”
BackgroundThe interplay between the microbiome and the adaptive immune response in cancer development
Russo, E., Taddei, A., Ringressi, M. N., Ricci, F., & Amedei, A. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16635082 · Cited by 76
“IL-23 was found to be increased in human colon adenocarcinoma and, through induction of proinflammatory responses, promotes tumor growth [Langowski et al. 2006].”
BackgroundFaraoni, E. Y., O’Brien, B. J., Strickland, L. N., Osborn, B. K., Mota, V., Chaney, J., Atkins, C. L., Cen, P., Rowe, J. H., Cardenas, J. C., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0379 · Cited by 75
Th1 cytokine-based immunotherapy for cancer
Xu, H. (2014) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(14)60305-2 · Cited by 71
Hmgb1-IL-23-IL-17-IL-6-Stat3 Axis Promotes Tumor Growth in Murine Models of Melanoma
Tang, Q., Li, J., Zhu, H., Li, P., Zou, Z., & Xiao, Y. (2013) · Mediators of Inflammation · doi:10.1155/2013/713859 · Cited by 69
“IL23 has emerged as a new player in promoting tumor growth and development [36].”
BackgroundThe role of Th17 cells in viral infections
Aghbash, P. S., Hemmat, N., Nahand, J. S., Shamekh, A., Memar, M. Y., Babaei, A., & Baghi, H. B. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107331 · Cited by 70
Kreher, M. A., Noland, M. M., Konda, S., Longo, M. I., & Valdés‐Rodríguez, R. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.11.044 · Cited by 66
ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner
Mahadevan, N. R., Rodvold, J. J., Almanza, G., Fernandez-Perez, A., Wheeler, M. C., & Zanetti, M. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-229 · Cited by 70
“Next, we probed TC1 cells using qPCR for transcription of two pro-inflammatory cytokines, Il-6 and Il23p19, both of which have been implicated in tumor progression [25,26].”
MethodWalch‐Rückheim, B., Ströder, R., Theobald, L., Pahne‐Zeppenfeld, J., Hegde, S., Kim, Y.-J., Bohle, R. M., Juhasz‐Böss, I., Solomayer, E., & Smola, S. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1913 · Cited by 69
Neutrophil interactions with T cells, platelets, endothelial cells, and of course tumor cells
Segal, B. H., Giridharan, T., Suzuki, S., Khan, A. N. H., Zsíros, E., Emmons, T. R., Yaffe, M. B., Gankema, A. A. F., Hoogeboom, M., Goetschalckx, I., et al. (2022) · Immunological Reviews · doi:10.1111/imr.13178 · Cited by 72
New Interleukin-23 Pathway Inhibitors in Dermatology: Ustekinumab, Briakinumab, and Secukinumab
Kurzeja, M., Rudnicka, L., & Olszewska, M. (2011) · American Journal of Clinical Dermatology · doi:10.2165/11538950-000000000-00000 · Cited by 71
Zheng, J., Jiang, L., Zhang, L., Yang, L., Deng, J., You, Y., Li, N., Wu, H., Li, W., Lü, J., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs307 · Cited by 66
“Moreover, previous studies have indicated that IL-23R can promote tumor growth and may decrease immunosurveillance by CD8+ T cells (8).”
BackgroundThe role of angiogenesis in the pathogenesis of psoriasis
Chua, R. A., & Arbiser, J. L. (2009) · Autoimmunity · doi:10.1080/08916930903002461 · Cited by 65
“[13] Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M.”
BackgroundFloss, D. M., Mrotzek, S. M., Klöcker, T., Schröder, J., Grötzinger, J., Rose‐John, S., & Scheller, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.432153 · Cited by 66
“IL-23 also appears to promote tumor incidence and growth (15), but at least one report indicates that IL-23 has also anti-tumorigenic activity against pediatric B-acute lymphoblastic leukemia (B-ALL) cells (16), demonstrating (e.”
BackgroundPouyet, L., Roisin-Bouffay, C., Clément, A., Millet, V., Garcia, S., Chasson, L., Issaly, N., Rostan, A., Hofman, P. M., Naquet, P., et al. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21031 · Cited by 68
“AOM-induced tumors are frequently infiltrated by T lymphocytes that may influence the CAC protocol by sustaining production of inflammatory effectors by myeloid cells and/or providing a supplementary source of trophic factors for tumor cells.(39,40) Interestingly, very few CD4þ T cells were detected in infiltrates of…”
BackgroundNatividad, A., Freeman, T. C., Jeffries, D. J., Burton, M. J., Mabey, D. C. W., Bailey, R. L., & Holland, M. J. (2010) · Infection and Immunity · doi:10.1128/iai.00844-10 · Cited by 69
“IL-23 promotes inflammatory responses that include upregulation of MMP9 (45), polymorphism of which is associated with scarring trachoma.”
BackgroundImmune Chaperone gp96 Drives the Contributions of Macrophages to Inflammatory Colon Tumorigenesis
Morales, C., Rachidi, S., Hong, F., Sun, S., Ouyang, X., Wallace, C., Zhang, Y., Garret-Mayer, E., Wu, J., Liu, B., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1677 · Cited by 62
“They further showed that IL-23 promoted tumorigenesis in the 9,10-dimethyl-1,2benzanthracene and 12-O-tetradecanoyl-phorbol acetate model of skin papillomas, whereas IL-12 proved protective (45).”
BackgroundIL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model
Wang, D., Shao, Y., Zhang, X., Lu, G., & Liu, B. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-019-02206-w · Cited by 70
Self-citationPark, H., Lee, S.-H., Lee, J., Moon, H., & Ro, S. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813764 · Cited by 70
“IL-23 belongs to the IL-12 family of cytokines and acts as a crucial molecular link between tumor-promoting pro-inflammatory processes and the impairment of adaptive immune surveillance [140].”
BackgroundEnvironment, inflammation, and cancer
Sansone, P., & Bromberg, J. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.11.001 · Cited by 76
MicroRNA-155 regulates host immune response to postviral bacterial pneumonia via IL-23/IL-17 pathway
Podsiad, A. B., Standiford, T. J., Ballinger, M. N., Eakin, R., Park, P. K., Kunkel, S. L., Moore, B. B., & Bhan, U. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00224.2015 · Cited by 63
Inflammation and Prostate Cancer
Tewari, A. K., Stockert, J. A., Yadav, S. S., Yadav, K. K., & Khan, I. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-95693-0_3 · Cited by 68
Control of the Antitumor Immune Response by Cancer Metabolism
Domblides, C., Lartigue, L., & Faustin, B. (2019) · Cells · doi:10.3390/cells8020104 · Cited by 68
“Indeed, models of a tumor-xenograft mouse which harbor a deletion of IL-23 have restricted tumor growth [60].”
Levy, B. D. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00390 · Cited by 66
“IL-23 is also involved in the pathobiology of chronic inflammatory diseases, including colitis, encephalitis, psoriasis, rheumatoid arthritis, and cancer (Langrish et al., 2005; Chan et al., 2006; Langowski et al., 2006; Yago et al., 2007), and IL-23 is critical for the survival of TH17 cells (Langrish et al.”
BackgroundSilencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation
Hashimoto, M., Ayada, T., Kinjyo, I., Hiwatashi, K., Yoshida, H., Okada, Y., Kobayashi, T., & Yoshimura, A. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01098.x · Cited by 70
Cytokine gene‐mediated immunotherapy: Current status and future perspectives
Jinushi, M., & Tahara, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01202.x · Cited by 67
Colitis-associated neoplasia: molecular basis and clinical translation
Foersch, S., & Neurath, M. F. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1636-x · Cited by 70
Th17 cells: A new therapeutic target in inflammatory dermatoses
Asarch, A., Barak, O. G., Loo, D. S., & Gottlieb, A. B. (2008) · Journal of Dermatological Treatment · doi:10.1080/09546630802206660 · Cited by 64
Badoual, C., Sandoval, F., Péré, H., Hans, S., Gey, A., Merillon, N., Ryswick, C. V., Quintin‐Colonna, F., Bruneval, P., Brasnu, D. F., et al. (2010) · Head & Neck · doi:10.1002/hed.21346 · Cited by 61
Anti-interleukin-23 agents for the treatment of ulcerative colitis
Hanžel, J., & D’Haens, G. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1697227 · Cited by 64
Immunometabolism in biofilm infection: lessons from cancer
Mirzaei, R., Sabokroo, N., Ahmadyousefi, Y., Motamedi, H., & Karampoor, S. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00435-2 · Cited by 63
The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer
Seya, T., & Matsumoto, M. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0652-9 · Cited by 64
“smoldering inXammation around the tumor lesion to promote tumor incidence and growth [68].”
BackgroundZhang, L., Li, J., Li, L., Zhang, J., Wang, X., Yang, C., Li, Y., Lan, F., & Lin, P. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu017 · Cited by 59
“In addition, the procanceration role of IL-23 has also been investigated extensively (8,9).”
BackgroundRole of Cytokines and Toll-Like Receptors in the Immunopathogenesis of Guillain-Barré Syndrome
Nyati, K. K., & Prasad, K. N. (2014) · Mediators of Inflammation · doi:10.1155/2014/758639 · Cited by 64
“Knockout mice deficient in either p40/p19 or subunit of the IL23 receptor (IL23R and IL12R-β1) develop less severe symptoms of multiple sclerosis and inflammatory bowel disease highlighting the importance of IL23 in the inflammatory pathway [22, 23].”
BackgroundAbad, C., Nobuta, H., Li, J., Kasai, A., Yong, W. H., & Waschek, J. A. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012531 · Cited by 63
“implicated in tumor growth [6, 19, 20].”
Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention
Wang, S.-H., & Lin, S. (2013) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-2-29 · Cited by 64
“Interleukin 23 can suppress both innate and adaptive anti-tumor effectors responses, whereas interleukin 12 prevents cancer outgrowth [44,45].”
BackgroundTGF-β and tumors — an ill-fated alliance
Moutsopoulos, N. M., Wen, J., & Wahl, S. M. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.04.003 · Cited by 58
Velikova, T. V., Miteva, L. D., Stanilov, N., Spassova, Z., & Stanilova, S. A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i16.1912 · Cited by 63
Fulkerson, C. M., Dhawan, D., Ratliff, T. L., Hahn, N. M., & Knapp, D. W. (2017) · International Journal of Genomics · doi:10.1155/2017/6589529 · Cited by 58
Beyer, B. M., Ingram, R. N., Ramanathan, L., Reichert, P., Le, H. V., Madison, V., & Orth, P. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.08.001 · Cited by 56
Yan, J., Liu, X., Xiao, G., Li, N., Deng, Y.-N., Han, L., Yin, L.-C., Ling, L., & Liu, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096080 · Cited by 62
“The inflammatory environment driven by relevant levels of endogenous IL-17 may promote tumor progression by stimulating angiogenesis; in contrast, overexpression of IL-17 may lead to inflammatory reactions that trigger cancer-cell destruction [31] and [35].”
BackgroundDas, R., KOMOROWSKI, R. A., Hessner, M. J., Subramanian, H., Huettner, C. S., Cua, D., & Drobyski, W. R. (2010) · Blood · doi:10.1182/blood-2009-11-255422 · Cited by 55
Chen, J., Lü, Y., Zhang, H., Ding, Y., Ren, C., Hua, Z., Zhou, Y., Deng, B., Jin, G., Hu, Z., et al. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20661 · Cited by 58
“murine models of epithelial cancers [41].”
Immunometabolism: A new target for improving cancer immunotherapy
Guo, C., Chen, S., Liu, W., Ma, Y., Li, J., Fisher, P. B., Fang, X., & Wang, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.004 · Cited by 59
“IL-23 promotes cancer supporting inflammation through upregulation of the matrix metalloprotease MMP-9, expansion of inflammatory Th17 cells, and by preventing tumor infiltration of CTLs (Langowski et al., 2006; Numasaki et al., 2003).”
BackgroundInfluentialMartin, P. L., & Bugelski, P. J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01812.x · Cited by 54
“In breast cancer tumour-bearing mice, treatment with an anti-murine IL-12/23 p40 antibody produced an increase in the growth of the tumours (Langowski et al., 2006).”
BackgroundBartolini, I., Risaliti, M., Ringressi, M. N., Melli, F., Nannini, G., Amedei, A., Muiesan, P., & Taddei, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i20.2498 · Cited by 55
Niehues, H., Rikken, G., van Vlijmen‐Willems, I. M. J. J., Rodijk‐Olthuis, D., van Erp, P. E. J., Zeeuwen, P. L. J. M., Schalkwijk, J., & van den Bogaard, E. H. J. (2021) · JID Innovations · doi:10.1016/j.xjidi.2021.100066 · Cited by 63
“Specific evidence toward the role of IL-17A in epidermal hyperproliferation is yet scarce (Lai et al., 2012; Langowski et al., 2006; Wu et al., 2015).”
BackgroundThe use of ustekinumab in autoimmune disease
Ryan, C., Thrash, B., Warren, R. B., & Menter, A. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003724670 · Cited by 57
“IL-23, however, promoted tumor growth, suggesting that inhibition of this cytokine may serve to inhibit carcinogenesis [77].”
BackgroundVerma, C., Eremin, J. M., Robins, A., Bennett, A. J., Cowley, G., El‐Sheemy, M., Jibril, J. A., & Eremin, O. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-16 · Cited by 60
Li, J., Zhang, L., Zhang, J., Wei, Y., Li, K., Huang, L., Zhang, S., Gao, B., Wang, X., & Lin, P. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs384 · Cited by 55
“IL-12 induces antitumor immune responses, whereas IL-23 has been identified recently as a link between tumor-associated inflammation and tumor immune escape (15,27).”
BackgroundTeng, M. W. L., von Scheidt, B., Duret, H., Towne, J. E., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3994 · Cited by 54
Innate lymphoid cells in tissue homeostasis and diseases
Ignácio, A., Breda, C. N. D. S., & Câmara, N. O. S. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i23.979 · Cited by 59
Guselkumab for the treatment of psoriasis – evidence to date
Nogueira, M., & Torres, T. R. (2019) · Drugs in Context · doi:10.7573/dic.212594 · Cited by 57
Clark, R. T., Nance, J. P., Noor, S., & Wilson, E. H. (2011) · ASN NEURO · doi:10.1042/an20100027 · Cited by 63
“Previous studies have shown MMP production is stimulated in the brain by several aspects of the immune response known to be present during T. gondii infection, including IL-1 (Szenasi et al., 2008); IL-23 (Langowski et al., 2006); TNF-a (Szenasi et al., 2008) and COX-2 (Peng et al., 2008); thus it is perhaps not surpr…”
BackgroundInfluentialElevated Circulating Levels of Inflammatory Markers in Patients with Acute Coronary Syndrome
Shahi, H. A., Shimada, K., Miyauchi, K., Yoshihara, T., Sai, E., Shiozawa, T., Naito, R., Aikawa, T., Ouchi, S., Kadoguchi, T., et al. (2015) · International Journal of Vascular Medicine · doi:10.1155/2015/805375 · Cited by 53
Sologuren, I., Rodríguez‐Gallego, C., & Lara, P. C. (2014) · Translational Cancer Research · doi:10.21037/2091 · Cited by 65
“The latter effect was proposed to occur through pro-inflammatory and proangiogenic effector pathways that sustain the tumor, which may be mediated by IL-17 (36,42).”
BackgroundLin, S., Chen, K., Xu, Z., Chen, H., Zhou, L., Xie, H., & Zheng, S. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0379 · Cited by 55
“TH17 cells in solid tumor are involved in tumor promotion or progression (31, 32).”
BackgroundWong, L. Y., Hatfield, J. K., & Brown, M. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.481440 · Cited by 56
Vizio, B., Novarino, A., Giacobino, A., Cristiano, C., Prati, A., Ciuffreda, L., Montrucchio, G., & Bellone, G. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.553 · Cited by 56
“…of IL-23 (rather than IL-12) by DC and tumor antigen-stimulated macrophages in tumor-draining lymph nodes and microenvironment, respectively, may result in subversion of tumor-specific T-cell differentiation, with a prevalence of Treg and Th17-type responses over the antitumor Th1 response (35).”
Berg, M. H., Rincon, S. V. D., & Miller, W. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003551 · Cited by 59
Fujita, K., Ewing, C. M., Sokoll, L. J., Elliott, D. J., Cunningham, M., Marzo, A. M. D., Isaacs, W. B., & Pavlovich, C. P. (2008) · The Prostate · doi:10.1002/pros.20755 · Cited by 65
“IL-17 is a pro-inflammatory cytokine, that plays a crucial role in the development of autoimmunity and allergic reactions, and the expression of IL17 from Th17 is stimulated by IL23, which promotes tumor incidence and growth [19].”
BackgroundThe Interleukin-12 Family: New Players in Transplantation Immunity?
Goriely, S., & Goldman, M. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01651.x · Cited by 56
“Furthermore, in contrast with IL-12p70 and IFN-c , which are known to exert anti-tumor activity, IL-23 and IL-17 were recently found to promote cancer incidence and growth by stimulating tumor angiogenesis and inhibiting tumor infiltration by CD8+ cytotoxic T cells (24).”
ResultIn support of descriptive studies; relevance to translational research
Marincola, F. M. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-21 · Cited by 53
Yuan, Z., Mehta, H. J., Mohammed, K. A., Nasreen, N., Roman, R. M., Brantly, M., & Sadikot, R. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094241 · Cited by 56
“IL-6 and IL-23 have been shown to be involved in immuno-editing in carcinoma microenvironments and is associated with poor prognosis [53] [54] [55] [56].”
BackgroundJauch, D., Martin, M., Schiechl, G., Kesselring, R., Schlitt, H. J., Geissler, E. K., & Fichtner‐Feigl, S. (2011) · Gut · doi:10.1136/gutjnl-2011-300612 · Cited by 56
Ziblat, A., Núñez, S. Y., Iraolagoitia, X. L. R., Spallanzani, R. G., Torres, N. I., Sierra, J. M., Secchiari, F., Domaica, C. I., Fuertes, M. B., & Zwirner, N. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01959 · Cited by 52
“Interleukin-23 has been involved in immunity against tumors (29, 47) and acute infections (30, 31) but also contributes to tumor promotion and growth (40, 48) and the development of autoimmune diseases, mainly through the induction of a Th17 response (30, 49).”
BackgroundInfiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23
Kansara, M., Thomson, K., Pang, P., Dutour, A., Mirabello, L. J., Acher, F., Pin, J., Demicco, E. G., Yan, J., Teng, M. W. L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0154 · Cited by 55
“Although the oncogenic effects of IL23 have been reported in multiple cancer types (2, 21, 22, 37), it is interesting that subjects with psoriasis, an autoimmune disease driven by IL23, are specifically at risk of osteosarcoma and chondrosarcomas (HR 4.”
BackgroundDendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy
Terhune, J. H., Berk, E., & Czerniecki, B. J. (2013) · Vaccines · doi:10.3390/vaccines1040527 · Cited by 62
“Furthermore, while IL-12 has been shown to promote the infiltration of cytotoxic T-cells into tumors, IL-23 was shown to inhibit the migration of cytotoxic T-cells to tumor tissue and promote angiogenesis [73].”
BackgroundTumor Microenvironment as a New Target for Tumor Immunotherapy of Polysaccharides
Liu, L., Nie, S., & Xie, J. (2015) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2015.1077191 · Cited by 53
“IL-23 in inflammatory conditions was closely related to the formation of tumor (Langowski et al., 2006).”
BackgroundZang, M., Li, Y., He, H., Ding, H., Chen, K., Du, J., Chen, T., Wu, Z., Liu, H., Wang, D., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.004 · Cited by 54
Self-citationTh17 and Foxp3+ T regulatory cell dynamics and distribution in myelodysplastic syndromes
Bouchliou, I., Miltiades, P., Nakou, E., Spanoudakis, E., Goutzouvelidis, A., Vakalopoulou, S., Garypidou, V., Kotoula, V., Bourikas, G., Tsatalas, C., et al. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.03.001 · Cited by 54
“Accordingly, the proinflammatory IL-23 and IL-17 may promote tumor growth via STAT3 related mechanisms [32] or by increasing angiogenesis and decreasing cytotoxic T cell infiltration [33], whereas both Th17 cells and IL-17 have been shown to possess tumor-inhibitory effects [34–36].”
Posttranscriptional Regulation of IL-23 Expression by IFN-γ through Tristetraprolin
Qian, X., Ning, H., Zhang, J., Hoft, D. F., Stumpo, D. J., Blackshear, P. J., & Liu, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002672 · Cited by 50
“Furthermore, it has been reported that IL-23 expression was highly expressed in many tumors, including breast tumor, prostate cancer, and liver and skin cancers, and the levels of IL-23 were correlated with tumor progression (10, 11).”
BackgroundNikamo, P., Lysell, J., & Ståhle, M. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.103 · Cited by 54
“Knockout mice deficient for IL-23, for either p40 or p19, or for either subunit of the IL-23 receptor develop less severe symptoms of multiple sclerosis and inflammatory bowel disease emphasizing the general importance of IL-23 in inflammation (Langowski et al., 2006; Kikly et al., 2006), and therapy blocking the p40…”
BackgroundDuffield, A. S., Ascierto, M. L., Anders, R. A., Taube, J. M., Meeker, A. K., Chen, S., McMiller, T. L., Phillips, N. A., Xu, H., Ogurtsova, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007260 · Cited by 53
Colorectal Cancer and Probiotics: Are Bugs Really Drugs?
Lamichhane, P., Maiolini, M., Alnafoosi, O., Hussein, S., Alnafoosi, H., Umbela, S., Richardson, T., Alla, N., Lamichhane, N., Subhadra, B., et al. (2020) · Cancers · doi:10.3390/cancers12051162 · Cited by 50
“IL-23 has been shown to promote tumor growth, increase angiogenesis, increase matrix metalloproteinase (MMP9; an enzyme for extracellular matrix degradation) production, and curb cytotoxic T-cell recruitments to the tumors [65].”
BackgroundInterleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells
Cocco, C., Canale, S., Frasson, C., Carlo, E. D., Ognio, E., Ribatti, D., Prigione, I., Basso, G., & Airoldi, I. (2010) · Blood · doi:10.1182/blood-2009-10-248245 · Cited by 50
Cocco, C., Carlo, E. D., Zupo, S., Canale, S., Zorzoli, A., Ribatti, D., Morandi, F., Ognio, E., & Airoldi, I. (2011) · Leukemia · doi:10.1038/leu.2011.363 · Cited by 53
Epigenetic regulation of transposable element derived human gene promoters
Huda, A., Bowen, N. J., Conley, A. B., & Jordan, I. K. (2011) · Gene · doi:10.1016/j.gene.2010.12.010 · Cited by 50
Metadata
- Authors
- Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M.
- Corresponding author
- Oft, Martin
- Venue
- Nature
- Published
- 2006-05-10
- Volume
- 442
- Issue
- 7101
- Pages
- 461-465
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1984467626
- Cited by
- 1,018
- References
- 30
- Citations by year
- 2026: 23 · 2025: 18 · 2024: 32 · 2023: 46 · 2022: 42 · 2021: 44 · 2020: 41 · 2019: 52 · 2018: 41 · 2017: 41 · 2016: 41 · 2015: 47 · 2014: 62 · 2013: 72 · 2012: 65
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- IL-23, tumour-associated inflammation, tumor surveillance, CD8+ T cell infiltration, intraepithelial lymphocytes, tumor microenvironment, angiogenesis, MMP-9, IL-12, chemical carcinogenesis, IL23R, tumor growth, cancer immunotherapy
- MeSH terms
- Animals, Cell Division, Humans, Inflammation, Interleukins, Mice, Inbred C57BL, Neoplasms, Signal Transduction, CD8-Positive T-Lymphocytes, Interleukin-12, Genetic Predisposition to Disease, Mice, Interleukin-23, Interleukin-23 Subunit p19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.